Srividya Swaminathan

7PUBLICATIONS
31CO-AUTHORS
Tumour immunologyMolecular targetsInnate immunityHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 01, 2026
Selective sensitivity of Ph-like B-cell acute lymphoblastic leukemia to BRG1 inhibition identifies a therapeutic vulnerability.

|Mar 02, 2026
Harnessing Natural Killer Cell-Mediated Innate Immune Responses for Cancer Treatment: Advances and Challenges.

Anil Kumar, Adeleh Taghi Khani, Srividya Swaminathan

|Mar 28, 2025
DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition.

V S S Abhinav Ayyadevara, Gerald Wertheim, Shikha Gaur

|Jan 24, 2025
NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.

Rui Ma, Zhenlong Li, Hejun Tang

|May 22, 2023
Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia.

Anil Kumar, Adeleh Taghi Khani, Caroline Duault

|Mar 21, 2023
Isoform-specific knockdown of long and intermediate prolactin receptors interferes with evolution of B-cell neoplasms.

Adeleh Taghi Khani, Anil Kumar, Ashly Sanchez Ortiz

Pageof 2

Frequent Collaborators

3 joint publications

Sarah K Tasian

2 joint publications

Caroline Duault

2 joint publications

Anil Kumar

2 joint publications

Adeleh Taghi Khani